
The Danish pharmaceutical giant Novo Nordisk, led by new CEO Maziar Mike Doustdar, is spearheading a radical transformation of its long-term research and development strategy.
The company is moving 'beyond the scale' to reposition its flagship GLP-1 molecules, such as semaglutide, as comprehensive treatments for MASH (liver disease), chronic kidney disease, and cardiovascular health, rather than just weight-loss aids.